Dr. Soohyeon Lee
Clinical assistant professor, Severance Hospital/Y
Oncology and Molecular Radiation Sciences
Korea University
Norway
Biography
Present Medical Director, Oncology medical lead, Pfizer Korea Responsible person for safety management in New Drug Re-examination in Pfizer Korea - Certified by MFDS (Start date : 06-Aug-2015) 3/2011-2/2014 Assistant Professor of Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea Present Medical Director, Oncology medical lead, Pfizer Korea Responsible person for safety management in New Drug Re-examination in Pfizer Korea - Certified by MFDS (Start date : 06-Aug-2015) 3/2011-2/2014 Assistant Professor of Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea
Research Interest
Research Assistant Professor of Medicine, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea
Publications
-
Lee S, Kim MH, Koo JS, Jung KH, Park IH, Jeong J, Kimg SI, Park S, Park HS, Park BW, Kim JH, Sohn, Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevelance, clinicopathological features and prognostic implication, PLos One, 2015 Mar 24;10(3):e0120320. 9. Park Y, Kim H, Kim EH, Suh CO, Lee S, Effective treatment of solitary pituitary metastasis with panhypopituitarism in HER2-positive breast cancer by lapatinib, Cancer Res Treat 2015 Feb 16. 10. Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, Lee NR, Yun J, Woo IS, Park KH, Kim KH, Kim HY, Rha SY, Byun JH, Phase ll study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG) GY 10-10, Gynecol Oncol 2015 Feb;136(20):212-7. 11. Lim S, Lee S, Lim JY, Park JS, Seong JS, Chang WS, Han KH, Choi HJ, Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma, J Neurooncol 2014 Oct;120(1):199-207.
-
Heo SJ, Kim G, Lee CK, Chung KS, Choi HJ, Sohn J and Lee S, Prediction of short- and long-term survival for advanced cancer patients after ICU admission, Support Care Cancer, 2015 Jun;23(6):1647-55. 5. Park YH, Jung KH, Im SA, Sohn JH, Ro J, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS, KCSG, Im YH, Quality of life in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine chemotherapy: results from phase lll, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02), Breast Cancer Research and Treatment 2015 Jul;152(1):77-85. 6. Lee HS, Chun KH, Moon D, Yeon HK, Lee S, Lee S, Trends in receiving chemotherapy for advanced cancer patients at the end of life. BMC palliate Care 2015 Mar 13;14:4. 7. Joo B, Park MS, Lee S, Choi HJ, Lim S, Rha SY, Rachmilevitch I, Lee YH, Suh JS, Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with confirmal bone system: a preliminary report. Yonsei Med J 2015 Mar;56(2):503-9.
-
Lee S, Jung HH, Kim JY, Ahn JS, Park YH, Im YH. Statins affect ETS-1-overexpressing triple-negative breast cancer cells by restroring DUSP4 deficiency. Sci Rep, 2016 Sep 8;6:33035. 2. Lee CH, Ro YS, Cho J, Park Y, Hwang HJ, Choi HJ, Lee S. Characteristics of venous thromboembolism in pancreatic adenocarcinoma in East asian ethnics: a large population-based observational study, Medicine, 2016, 95(17):e3472. 3. Kim SH, Jung KH, Kim TY, Im SA, Choi IS, Chae YS, Baek SK, Kang SY, Park S, Park IH, Lee KS, Choi YJ, Lee S, Sohn JH, Park YH, Im YH, Ahn JH, Kim SB, Kim JH, Prognostic Value of Axillary Nodal Ratio After Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide (AC) Followed by Docetaxel (DOC): A Multicenter Retrospective Cohort Study.Cancer Res Treat, 2016 Mar 23. [Epub ahead of print].
